O
Olle Ringdén
Researcher at Karolinska Institutet
Publications - 497
Citations - 35910
Olle Ringdén is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 86, co-authored 491 publications receiving 33411 citations. Previous affiliations of Olle Ringdén include Sahlgrenska University Hospital & Uppsala University.
Papers
More filters
Journal ArticleDOI
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Katarina Le Blanc,Ida Rasmusson,Berit Sundberg,Cecilia Götherström,Moustapha Hassan,Mehmet Uzunel,Olle Ringdén +6 more
TL;DR: It is postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo and are transplanted in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver.
Journal ArticleDOI
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
Katarina Le Blanc,Francesco Frassoni,Lynne M. Ball,Franco Locatelli,Helene Roelofs,Ian D. Lewis,Edoardo Lanino,Berit Sundberg,Maria Ester Bernardo,Mats Remberger,Giorgio Dini,R. Maarten Egeler,Andrea Bacigalupo,Willem E. Fibbe,Olle Ringdén +14 more
TL;DR: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD.
Journal ArticleDOI
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
TL;DR: Undifferentiated and differentiated MSC do not elicit alloreactive lymphocyte proliferative responses and modulate immune responses, and the findings support that MSC can be transplantable between HLA-incompatible individuals.
Journal ArticleDOI
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
Olle Ringdén,Mehmet Uzunel,Ida Rasmusson,M Remberger,Berit Sundberg,Helena Lönnies,Hanns-Ulrich Marschall,Aldona Dlugosz,Attila Szakos,Zuzana Hassan,Brigitta Omazic,Johan Aschan,L Barkholt,Le Blanc K +13 more
TL;DR: MSC is a very promising treatment for severe steroid-resistant acute GVHD and five patients are still alive between 2 months and 3 years after the transplantation and their survival rate was significantly better than that of 16 patients with steroid- resistant biopsy-proven gastrointestinal GV HD, not treated with MSC during the same period.
Journal ArticleDOI
Immunomodulation by mesenchymal stem cells and clinical experience
K. Le Blanc,Olle Ringdén +1 more
TL;DR: In vivo, MSCs prolong skin allograft survival and have several immunomodulatory effects, which are presented and discussed in the present study.